Diligence memo · auto-generated · as of July 2, 2026

Nuvaira, Inc.

Nuvaira, Inc. looks fair against its niche peers and is active on financing cadence.

SourceRaising on rhythm with a 36.5× step-up on the last round — momentum worth tracking before it's priced in.

Businessfiled

Nuvaira, Inc. operates in Other Health Care, based in MINNEAPOLIS.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Nuvaira, Inc. has raised $178M in disclosed capital across 10 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $42M on 2014-04-02.

Most recent recorded round closed around 2026-02-20.

Valuation (modeled)modeled

Provath models Nuvaira, Inc. at approximately $192M (range $130M–$233M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.85× the median modeled value of Series C Other Health Care companies in 2025–2027 (20 peers) — value vs value, same stage and era. Within the normal band (85% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 17 months.

Last raise 4 mo ago; this sector typically re-raises about every 14 months.

Raising on or ahead of the sector's normal rhythm.

The last round stepped up 36.5× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 98% of Other Health Care peers (5377 compared).

Modeled value ranks above 87% of those peers.

Closest niche peers: RESTOR3D, Inc., ByHeart, Inc., SpyGlassPharma, Inc., VantAI Holdings, Inc., BioIntelliSense, Inc..

Peoplefiled

24 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.